Applied Sciences homework help.
4-5 pages
Outline
Trastuzumab Deruxtecan and Patient with HER2-Positive Breast Cancer
1. Introduction: [Introduce Trastuzumab Deruxtecan and its role in contributing to HER2-
Positive Breast Cancer, basic information of breast cancer, and explain why I am
interested in this topic or why it is important. (back up with epidemiologic data)
2. Subheading 1 – Major advantages of Trastuzumab Deruxtecan: [Discuss the main
pharmacological issues]
3. Subheading 2 – Major disadvantage of Trastuzumab Deruxtecan: Discuss
pharmacological issues) (I will look up for more biological data to back up my
statement).]
4. Subheading 3 – Consideration on Trastuzumab Deruxtecan for HER2-positive breast
cancer patients: [Discuss epidemiologic evidence, Discuss clinical use.
5. Conclusion: [Final take-home messages, briefly summarize major findings of review on
the effects of Trastuzumab Deruxtecan and HER2-positive breast cancer.
Tables: [Table summarizing the studies of the association between Trastuzumab Deruxtecan for
HER2-positive breast cancer patients.
Outline
Trastuzumab Deruxtecan and Patient with HER2-Positive Breast Cancer
1. Introduction: [Introduce Trastuzumab Deruxtecan and its role in contributing to HER2-
Positive Breast Cancer, basic information of breast cancer, and explain why I am
interested in this topic or why it is important. (back up with epidemiologic data)
2. Subheading 1 – Major advantages of Trastuzumab Deruxtecan: [Discuss the main
pharmacological issues]
3. Subheading 2 – Major disadvantage of Trastuzumab Deruxtecan: Discuss
pharmacological issues) (I will look up for more biological data to back up my
statement).]
4. Subheading 3 – Consideration on Trastuzumab Deruxtecan for HER2-positive breast
cancer patients: [Discuss epidemiologic evidence, Discuss clinical use.
5. Conclusion: [Final take-home messages, briefly summarize major findings of review on
the effects of Trastuzumab Deruxtecan and HER2-positive breast cancer.
Tables: [Table summarizing the studies of the association between Trastuzumab Deruxtecan for
HER2-positive breast cancer patients.
